pembrolizumab

GPTKB entity

Statements (52)
Predicate Object
gptkbp:instanceOf gptkb:monoclonal_antibody
immunotherapy
gptkbp:administeredBy advanced cancers
adjuvant therapy
metastatic cancers
infusion every 3 or 6 weeks
neoadjuvant therapy
gptkbp:approvedBy gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:cancer
gptkb:FDA
gptkb:head_and_neck_squamous_cell_carcinoma
gptkb:classical_Hodgkin_lymphoma
gptkb:microsatellite_instability-high_cancer
gptkb:primary_mediastinal_large_B-cell_lymphoma
2014
melanoma
gastric cancer
gptkbp:ATCCode L01XC18
gptkbp:brand gptkb:Keytruda
gptkbp:CASNumber 1374853-91-4
gptkbp:contraindication severe hypersensitivity to pembrolizumab
gptkbp:developedBy gptkb:Merck_&_Co.
gptkbp:drugClass immunotherapy
https://www.w3.org/2000/01/rdf-schema#label pembrolizumab
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction PD-1 inhibitor
gptkbp:molecularWeight 146,000 g/mol
gptkbp:monitors thyroid function tests
liver function tests
immune-related adverse events
pulmonary symptoms
renal function tests
gptkbp:patentExpired 2028 (US)
gptkbp:pregnancyCategory D (US)
gptkbp:routeOfAdministration intravenous
gptkbp:sideEffect nausea
diarrhea
fatigue
pruritus
hepatitis
nephritis
hypothyroidism
rash
inflammatory bowel disease
pneumonitis
endocrinopathies
gptkbp:target gptkb:programmed_cell_death_protein_1_(PD-1)
gptkbp:UNII 4Z3Z14G2PO
gptkbp:bfsParent gptkb:Keytruda
gptkb:Lenvima
gptkbp:bfsLayer 5